Who are MAL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levulan® Kerastick®, verteporfin PDT, Methyl Aminolaevulinate 16% Cream, Verteporfin for injection, Verteporfin Photodynamic Therapy, Metvix and conventional PDT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MAL — Competitive Intelligence Brief

MAL (MAL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photosensitizing agent. Area: Oncology.

marketed Photosensitizing agent Protoporphyrin IX (via aminolevulinic acid pathway) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MAL (MAL) — Photocure. MAL (methyl aminolevulinate) is a photosensitizing prodrug that accumulates in abnormal cells and generates reactive oxygen species when activated by red light, destroying target tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MAL TARGET	MAL	Photocure	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolevulinic acid pathway)
Levulan® Kerastick®	Levulan® Kerastick®	Medical Dermatology Specialists	marketed	Photosensitizing agent	Protoporphyrin IX (photodynamic therapy precursor)
verteporfin PDT	verteporfin PDT	QLT Inc.	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Methyl Aminolaevulinate 16% Cream	Methyl Aminolaevulinate 16% Cream	Galderma R&D	marketed	Photosensitizing agent	Protoporphyrin IX (via aminolaevulinic acid pathway)
Verteporfin for injection	Verteporfin for injection	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Verteporfin Photodynamic Therapy	Verteporfin Photodynamic Therapy	Novartis	marketed	Photosensitizing agent	Lipoprotein receptors on neovascular endothelial cells
Metvix and conventional PDT	Metvix and conventional PDT	Galderma R&D	phase 3	Photosensitizing agent	Protoporphyrin IX (via aminolevulinic acid pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photosensitizing agent class)

Galderma R&D · 4 drugs in this class
Novartis · 2 drugs in this class
QLT Inc. · 2 drugs in this class
Medical Dermatology Specialists · 1 drug in this class
Photocure · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MAL — Competitive Intelligence Brief. https://druglandscape.com/ci/mal. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab